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In immunocompromised patients, EBV may elicit B-cell transformation and proliferation. A
5-year-old microcephalic boy was admitted with fever and non-malignant polymorphic T-
cell lymphoproliferative disease associated with EBV. A presumptive diagnosis of primary
immunodeficiency with inability to control EBV wasmade and next-generation sequencing
led to the identification of a novel ZBTB24 mutation (ICF2-syndrome). This case shows
that susceptibility to EBV seems to be particular of ICF-2 as it has not been described in
the other types of ICF. It is mandatory to raise the hypothesis of an underlying PID in case
of severe EBV infection.
Keywords: case report, ICF-2, Primary immune deficiencies, EBV, lymphoproliferationINTRODUCTION
Epstein-Barr virus (EBV) is one of eight human herpesviruses that establishes lifelong persistent
infection in humans. More than 90% of adults have been infected with EBV, whose life cycle mimics
the natural differentiation pathway of B cells, giving the virus access to its site of latent infection, the
resting memory B cells (1).
Primary infection in early childhood is generally asymptomatic but later in life it usually causes
infectious mononucleosis. In some patients, EBV can induce lymphoproliferation, lymphoma, and
hemophagocytic lymphohistiocytosis (HLH) particularly in immunocompromised patients,
reflecting the importance of continuous immune surveillance for the regulation of the virus (2).
In healthy patients the propensity of EBV to induce B-cell proliferation seems to be counterbalanced
by an immune system that maintains the overall number of EBV-infected B lymphocytes in a steady
level (2).
After infecting B-cells (and epithelial cells), the EBV replicative cycle that follows results in the
expression of lytic proteins involved in immune evasion which interfere with antigen (Ag)
processing and presentation to CD8+ T cells. Then, EBV switches to latent infection of B cells
avoiding T-cell and NK-cell immunity, which is critical for colonization of the host. Although the
exact mechanisms are still being discussed latency can take several forms (2), starting as a growth-org April 2021 | Volume 12 | Article 6541671
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latent proteins (EBV nuclear Ags (EBNA) 1, 2, 3A, 3B, 3C, and
LP; latent membrane proteins (LMPs) 1 and 2) can be detected.
In this state infected B cells expand rapidly in extrafollicular
areas of oropharyngeal lymphoid tissues such as the tonsils, and
large numbers of infected B cells can be found in the blood
(latency III). Most of these infected cells are cleared by the
immune system (2). Other latency forms consist of latency II
which is a more restrict form of latency design to evade the
immune system and where only EBNA1 and LMPs are
expressed. Finally, only EBNA1 is expressed in latency I. In
fact, viral persistence is achieved largely through silent infection
of memory B cells where expression of viral Ags is extinguished
(latency 0); in healthy carriers, EBV is exclusively found within
this population in the blood (2).
Primary immunodeficiencies that present with EBV-driven
LPDs are related to defects in the growth, differentiation and
activities of B and/or T cells. Briefly, the host defense to EBV can
be compromised by germline mutations in genes that encode
proteins that are crucial for an adequate response (3): a) in the
initial interaction between EBV-infected or antigen-presenting B
cells and CD8+ T cells (CD27/CD70, 4-1BB/4-1BBL) and
downstream signaling (requiring MAGT1, ITK, and RasGRP1)
that will induce DNA synthesis by activation of CTPS1 and elicit
proliferation of EBV-specific CD81 T cells; b) or following
expansion of EBV-specific CD81 T cells by compromising
cytotoxicity of CD8+ T and NK cells as seen in patients with
mutations in the SAP pathway. SAP links SLAM-family
receptors on hematopoietic cells with downstream intracellular
signaling pathways to regulate T and NK cells. In the absence of
SAP, cytotoxic functions of CD81 T and NK cells induced by
engaging the SLAM-family receptors 2B4 (CD244) and NTB-A
are abolished. These two pathways are required for the
functioning of one-another as illustrated by the ASGRP1-
dependent induction of CTPS1, the impaired NKG2D and
2B4 expression secondary to CD27/CD70 deficiency or by
the impaired PLCg1 activation due to ITK or MAGT1
deficiency (3).
Moreover, in immunocompromised patients who present an
impaired defense against EBV, the virus may elicit cell
transformation and proliferation, leading to EBV-induced
lymphoproliferative disorders (EBV-LPDs) (2). These are
usually divided in reactive proliferations (including reactive
lesions with no malignant potential l ike infectious
mononucleosis and reactive lesions with varied malignant
potential), B cell proliferations (including Hodgkin lymphoma
and plasma cell neoplasms), T/natural killer (NK)-cell
proliferations and immunodeficiency-related lymphoid
proliferations. Combined T-cell and B-cell immunodeficiencies
account for about two thirds of PIDs associated with EBV-driven
lymphoproliferative disorders (4).
There are several primary immunodeficiencies in which EBV+
B-cell LPDs are an important feature, but very few germline
mutations have been associated to documented EBV+ T/NK-cell
LPD (4). We report the case of a boy with massive EBV+ T-cell
LPD caused by a novel homozygous ZTBZ24 mutation.Frontiers in Immunology | www.frontiersin.org 2CASE REPORT
Five-year-old boy with no relevant family background but with
personal history of epilepsy, severe psychomotor retardation,
microcephaly, micrognathia, hypertelorism, low-set ears,
epicanthal folds, and macroglossia (Figure 1A).
Admitted in the context of prolonged fever and generalized
lymphadenopathies (cervical, abdominal, and mediastinal). He
had no other complaints.
An extensive investigation was performed and an elevated
EBV viral load (50,000 copies/ml) despite a negative EBV
serology was found. Prior to receiving any immunosuppressive
treatment, immunologic evaluation was performed and revealed
normal serum levels of IgG, IgA and IgM, normal responses to
diphteria and tetanus and a severe T and NK-cell lymphopenia,
as well as B-cell lymphopenia, particularly low post-germinal
class-switched memory B cells (Table 1).
An excisional biopsy of a lymphadenopathy was suggestive of
non-mal ignan t po lymorph ic EBV (EBER+) T-ce l l
lymphoproliferative disease. This lymphoproliferation was
accompanied by infiltration of the digestive tract and he
developed severe upper and lower digestive bleeding with two
episodes of hemorrhagic shock, needing multiple blood
transfusions. A gastric ulcer biopsy confirmed a polymorphic T
infiltrate (EBER+) (Figure 1B) and rearrangements of T cell
receptors and flow cytometry excluded monoclonality. Based on
the presence of EBV-LPD in a patient with personal history of
microcephaly and psychomotor retardation a presumptive
diagnosis of primary immunodeficiency with inability to control
EBV was made. He was treated with rituximab for B lymphocyte
depletion with resolution of fever and of the gastrointestinal
bleeding, which were accompanied by marked decrease in the
EBV viral load (viral load 50,000> 1015 copies/mL (Figure 1D).
Hematopoietic stem cell transplantation (HSCT)was not proposed
due to the personal history of severe psychomotor retardation.
Based on the pathologic findings of EBV+ T-cell LPD, and
despite the absenceof documentedT-cell infection in the peripheral
blood (5), cyclophosphamide was added to rituximab when the
patient eventually presented a disease relapse, with fever, increasing
viral load and generalized lymphadenopathies. This led to a
dramatic clinical improvement and a decrease in viral load to 20
copies/ml (Figure 1D).Unfortunately, in the followingmonths, the
patient had several infectious episodes (namely central line related
sepsis), leading to intermittent discontinuation of the
immunosuppressive treatment and subsequent relapse of the
disease with massive lymphoproliferation (Figure 1C) and
increasing viral loads, eventually leading to his death.
A next-generation sequencing panel of EBV-susceptibility
related genes (Table S1) led to the identification of a novel
c.301G>A (p.(Ala101Thr)) homozygous ZBTB24 (NM_014797.2)
mutation. This residue is highly conserved and there is a
physicochemical difference between alanine and threonine (Table
S2). This is a very rare variant and no homozygotes have been
reported (total allele frequency of around 0.017%, 48 heterozygous;
0 homozygous). Most bioinformatics analysis predicted that the
patient’s mutation Ala101Thr was damaging (e.g., SIFT =April 2021 | Volume 12 | Article 654167
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of 17,49. This led to the diagnosis of immunodeficiency,
centromeric region instability and facial anomalies syndrome
(ICF) type 2. Both parents were found to harbor a heterozygotic
mutation which allowed family counseling. Unfortunately, the
patient died before karyotyping could be performed. We
performed post-mortem Southern blot analysis for SAT2/Alpha-
Satellite repeat methylation but did not find the characteristic ICF-
associated repeat DNA hypomethylation. This is probablyFrontiers in Immunology | www.frontiersin.org 3explained by the unusual nature of the mutation: a homozygous
missense variant in the BTB domain.DISCUSSION
ICF is a rare autosomal recessive disorder caused by defective
DNA methylation, with approximately 70 cases reported so far
(4). Hypomethylation of satellite regions on chromosomes 1, 9,A
D
B C
FIGURE 1 | (A) Microcephaly (B) Gastric biopsy: EBV-encoded small ribonucleic acid (EBER1) in situ hybridization shows positive nuclei EBER+ in the T cells
lymphocytes. Double staining EBER-ISH (blue) and CD3-IHC (brown) (C) Thorax CT with mediastinal infiltration. (D) Clinical evolution, EBV load and therapeutics.April 2021 | Volume 12 | Article 654167
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chromosomal instability in vitro. Like our patient, individuals
with this syndrome present facial anomalies such as ocular
hypertelorism, epicanthic folds, broad flat nasal bridge, low-set
ears, and macroglossia. Other traits of the disease comprise
neurodevelopment disorder, including motor delay, speech
delay, and intellectual disability (6). Moreover, patients with
ICF have an impaired humoral and cellular immunity (4),
leading to recurrent bacterial infections. Viral infections are
less common but can have a severe course.
So far, four types of ICF syndromes have been identified. ICF1
is caused by mutations in DNMT3B, which encodes the DNA
methyltransferase 3B and is the most frequent type of ICF
syndrome, accounting for more than half of patients. ICF2
accounts for approximately 30% of ICF patients and is caused
by mutations in ZBTB24, which encodes the zinc-finger-and
BTB-domain (6). The remaining patients have mutations in
CDCA7 (ICF3) or HELLS (ICF4) (7). Immunological findings
appear to be similar in ICF1 and ICF2, though humoral
immunodeficiency has been reported to be more severe in
ICF1 still intellectual disability seems to be greater in patients
with ICF2 (6).
ZBTB24 belongs to family of transcription factors, which
form homo- or heterodimers in the nucleus via their BTB
domain and bind to target genes via their DNA-binding C2H2
zinc-finger domains (6). ZBTB24 is highly expressed by B-cells
and downregulation seems to increase the expression of IRF-4
(interferon regulatory factor 4) and Blimp-1 (B lymphocyte-
induced maturation protein 1), two crucial factors involved in
the proliferation and differentiation of B cell. These lock the cell-
cycle in the G0/1- to S-phase without apoptosis induction (8).
Unlike our patient, that never had hypogammaglobulinemia,
most (but not all) of the 40 patients reported with ICF2
presented hypogammaglobulinemia (particularly IgM) (6, 9).
On the other hand, he had B cell lymphopenia with
particularly low counts of post-germinal B cells, similar to
what has been previously reported in these patients (9).
Interestingly, five other ICF2 patients have been reported with
EBV infection: the first was described as having “severe
mononucleosis” (9), the second had persistent EBV infection
(10), the third had an EBV-induced hemophagocytic
lymphohystiocytosis (11), the fourth had a chronic EBV
infection and developed an aggressive Hodgkin lymphoma
(4) and the last one had an EBV-driven lymphoproliferative
disorder with features of a CD20-negative large B-cell
lymphoma (12) (Table S3) This susceptibility to EBV seems
to be particular of ICF-2 as it has not been described in
the other types of ICF. Similar to our patient, one patient had
EBV+ T-cell lymphoproliferation (9) and other had progression
of the disease despite rituximab (10). Knowing that EBV
promotes epigenetic changes by changing methylation
patterns (13) and that ICF patients present a pericentromeric
repeat hypomethylation (14), it is possible to assume that
differences in methylation profiles between ICF2 and the
other types of this syndrome helps to explain their unique










CMV, HSV 1,HSV2, VZV, HHV6, HHV7 PCR – Negative
CMV IgM/IgG – Negative/
Positive
Enterovirus PCR in stools; Multiplex PCR for
respiratory virus
– Negative
Parvovirus IgG/IgM – Negative
HIV 1 and 2 – Negative
VHA IgM/IgG – Negative/
Positive
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underlying PID in case of severe EBV infection, as HSCT is
the only curative treatment in many of these cases. When HSCT
is not an available therapeutic option (as in this case) the
approach to chronic EBV infection is extraordinarily complex
and should be individualized. The experience in controlling EBV
in immunosuppressed patients is based on post-transplant
lymphoproliferative disorders (PTLD) experience, where the
mainstay is reduction of immunosuppression, which is an
impossibility in primary immunodeficiency recipients. When B
cell depletion with rituximab does not lead to a long-lasting
control of the disease, regimens used in lymphoma therapy, such
as cyclophosphamide, vincristine and prednisone, have been
used despite an unsatisfactory outcome in many of these
patients (15).
In summary, we report a patient who succumbed to EBV-T-
cell LPD that harbored a novel homozygous A101T mutation in
the ZBTB24 gene, causing ICF2. Future studies [such as the
luciferase assay described by Daxinger et al (16)] will hopefully
help us describe how this mutation affects ZBTB24’s role in
controlling expression of CDCA7. This adds to the 5 previously
reported cases in the literature, and we discuss the complex
approach to the treatment of these patients in the absence of
putative curative treatment.DATA AVAILABILITY STATEMENT
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